<DOC>
	<DOCNO>NCT00687401</DOCNO>
	<brief_summary>Subjects moderate-to-severe chronic psoriasis respond standard biologic therapy eligible enroll study . Subjects receive infliximab infusion ( 5 mg/kg body weight ) Weeks 0 , 2 , 6 , 14 follow 12-week follow-up period . The efficacy infliximab evaluate Psoriasis Area Severity Index ( PASI ) .</brief_summary>
	<brief_title>A Study Evaluate Infliximab Subjects With Moderate-to-Severe Psoriasis Not Responding Standard Biologic Therapy ( Study P04612 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>&gt; =18 75 year age , either gender , race . Psoriasis cover least 10 % total body surface area ( BSA ) PASI &gt; =12 Screening Baseline . Diagnosis moderatetosevere psoriasis least 6 month prior screen . Eligible infliximab fail least 1 follow : corticosteroid , methotrexate ( MTX ) , systemic retinoids , cyclosporine , psoralenultraviolet A ( PUVA ) , ultraviolet B ( UVB ) phototherapy , and/or biologics ( etanercept efalizumab ) . Eligible accord tuberculosis ( TB ) eligibility assessment , screen early detection reactivation rule . Chest xray within 3 month prior Screening evidence malignancy , infection , fibrosis . Screening Baseline test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within protocolspecified parameter . Free significant disease could interfere study evaluation . Willing give write informed consent able adhere protocol visit procedure . Women childbearing potential men must use adequate birth control must continue 6 month receive last dose study medication . Females childbearing potential must negative serum pregnancy test Screening negative urine pregnancy test Baseline . Standard concomitant psoriasis therapy . Active latent TB . History chronic infectious disease , opportunistic infection , serious infection within 2 month enrollment . History lymphoproliferative disease . Malignancy past 5 year ( except treat basal cell carcinoma [ BCC ] ) . Treatment tumor necrosis factor ( TNF ) antagonists within previous 6 week . Current druginduced psoriasis . Females pregnant nursing female male plan pregnancy within 6 month last infusion infliximab . Previously treat infliximab . Concomitant diagnosis congestive heart failure ( CHF ) include medicallycontrolled asymptomatic subject . History chronic recurrent infectious disease . Have serious infection hospitalize receive intravenous antibiotic infection 2 month prior Screening . Have opportunistic infection within 6 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>